Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 11, Issue 6, 1993, Pages 1179-1188

  Miller, Antonius A ^a   Tolley, Elizabeth A ^a   Niell, Harvey B ^a   Griffin, John P ^a   Mauer, Alvin M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; ETOPOSIDE; FEMALE; HUMAN; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027153911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1993.11.6.1179     Document Type: Article

References (32)

1. Fleming RA, Miller AA, Stewart CF: Etoposide: An update. Clin Pharm 8:274-293, 1989
2. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
3. Clark PI, Joel SP, Slevin ML: A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small cell lung cancer. Proc Am Soc Clin Oncol 8:66, 1989 (abstr)
4. Hainsworth JD, Johnson DH, Frazier SR, et al: Chronic daily administration of oral etoposide - A phase I trial. J Clin Oncol 7:396-401, 1989
5. Johnson DH, Greco FA, Strupp J: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1940
6. Einhorn LW, Pennington K, McClean J: Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 17:32-35, 1990
7. Smit EF, Carney DN, Harford P, et al: A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631-633, 1989
8. Clark PI, Cottier B, Joel SP, et al: Prolonged administration of single-agent oral etoposide in patients with untreated small cell lung cancer. Proc Am Soc Clin Oncol 9:226, 1990 (abstr)
9. Miller JC, Einhorn LH: Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17:36-39, 1990
10. Hainsworth JD, Johnson DH, Frazier SR, et al: Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 26:818-821, 1990
11. Saxman S, Logie K, Stephens D, et al: Phase II trial of daily oral etoposide in patients with surgically unresectable non-small cell lung cancer. Proc Am Soc Clin Oncol 9:238, 1990 (abstr)
12. Waits TM, Johnson DH, Hainsworth JD, et al: Prolonged administration of oral etoposide in non-small cell lung cancer: A phase II trial. J Clin Oncol 10:292-296, 1992
13. Murphy PB, Hainsworth JD, Greco FA, et al: Cisplatin (P) & prolonged administration of oral etoposide (E) in extensive small cell lung cancer (ESCLC) patients (PT): A phase II trial. Proc Am Soc Clin Oncol 10:257, 1991 (abstr)
14. Walls J, Devore R, Hainsworth JD, et al: Carboplatin (CBDCA) plus prolonged administration of oral etoposide (E) in the treatment of non-small cell lung cancer (NSCLC): A phase I/II trial. Proc Am Soc Clin Oncol 10:257, 1991 (abstr)
15. Van derGaast A, Kok TC, Splinter TAW: Maximum tolerable duration of orally administered etoposide. Proc Am Soc Clin Oncol 10:106, 1991 (abstr)
16. Slevin ML, Joel SP, Whomsley R, et al: The effect of dose on the bioavailability of oral etoposide: Confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24:329-331, 1989
17. Hande KR, Bennett RB, Krozley MG, et al: Improved bioavailability (BA) with low dose oral (PO) etoposide (E). Proc Am Soc Clin Oncol 10:96, 1991 (abstr)
18. Joel SP, Dolega-Ossowksi E, Jones K, et al: The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc Am Assoc Cancer Res 32:178, 1991 (abstr)
19. Harvey VJ, Slevin ME, Joel SP, et al: The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br J Cancer 52:363-367, 1985
20. Miller AA, Stewart CF, Tolley EA: Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 25:361-366, 1990
21. Sokal RR, Rohlf FJ: Single classification analysis of variance, in Biometry: The Principles and Practice of Statistics in Biological Research (ed 2). New York, NY, Freeman, 1981, pp 208-270
22. Holford NHG, Sheiner LB: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453, 1981
23. Draper NR, Smith H: Applied Regression Analysis (ed 2). New York, NY, Wiley, 1981, pp 141-192
24. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
25. Slevin ML: Low-dose oral etoposide: A new role for an old drug? J Clin Oncol 8:1607-1609, 1990 (editorial)
26. Greco FA, Johnson DH, Hainsworth JD: Chronic daily administration of oral etoposide. Semin Oncol 17:71-74, 1990
27. Ruckdeschel JC: Is chemotherapy for metastatic non small cell lung cancer 'worth if? J Clin Oncol 8:1293-1295, 1990 (editorial)
28. Ratain MJ, Mick R, Schilsky RL, et al: Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity. J Clin Oncol 9:1480-1486, 1991
29. Ratain MJ, Schilsky RL, Conley BA, et al: Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739-1753, 1990
30. Mick R, Ratain MJ: Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 83:1560-1564, 1991
31. Trump DL, Egorin MJ, Forrest A, et al: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9:2027-2035, 1991
32. O'Connel JP, Kris MG, Grall RJ, et al: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604-1614, 1986